Swiss biotech firm BioVersys has signed a research and licensing agreement with the Japanese pharmaceutical company Shionogi. +Get the most important news from Switzerland in your inbox Under the terms of the collaboration, BioVersys is entitled to upfront and short-term research payments of CHF5 million, as the Basel-based company announced on Wednesday. Should Shionogi exercise a license option, approval and sales-based payments of up to CHF479 million ($604 million) tiered royalties on future sales would be added. + BioVersys is first Swiss IPO of 2025 The two companies want to drive forward a BioVersys program for the treatment of non-tuberculous mycobacteria. These pathogens can cause lung and skin infections and pathological swelling of the lymph nodes, particularly in people with weakened immune systems. Translated from German by DeepL/jdp How we work We select the most relevant news for an international audience and use automatic translation tools to translate them into ...
